Multiple Myeloma Articles

FDA Approves Maintenance Lenalidomide for Myeloma
The FDA has approved lenalidomide (Revlimid) as a maintenance therapy for patients with multiple myeloma following autologous hematopoietic stem cell transplant.
Expert Highlights Immunotherapy Advances in Myeloma
Eric Smith, MD, PhD, discusses recently reported phase II data combining elotuzumab (Empliciti) with lenalidomide (Revlimid) and dexamethasone.
CHMP Recommends Approval of Maintenance Lenalidomide in Post-ASCT Myeloma
The EMA’s Committee for Medicinal Products for Human Use has recommended approval of lenalidomide as a maintenance therapy following autologous stem cell transplant for patients with newly diagnosed multiple myeloma.
 
Expert Discusses Key Daratumumab Data Presented at ASH
Saad Z. Usmani, MD, discusses the latest developments with daratumumab in the treatment of patients with multiple myeloma, many of which were presented at the recent 2016 ASH Annual Meeting.
Expert Touts Value of Lenalidomide Maintenance in Myeloma
Lenalidomide as a maintenance treatment for patients with newly diagnosed symptomatic multiple myeloma demonstrated encouraging phase III findings in the Myeloma X1 trial, which were presented at the 2016 ASH Annual Meeting.
Transplant Remains Pivotal in Myeloma, Other Hematologic Cancers
The use of stem cell transplantation has changed over the last few years, with the emergence of novel therapies and treatment strategies. But even with the FDA approvals of new agents for multiple myeloma and select lymphomas, transplant remains to be a curative and reliable strategy.
Myeloma Expert Highlights Practice-Changing ASH Findings
The landscape of multiple myeloma continues to shift with more drug approvals, but pivotal results out of the 2016 ASH Annual Meeting will likely alter it even further.
Venetoclax Active in Heavily Treated Multiple Myeloma
The BCL-2 inhibitor venetoclax (Venclexta) demonstrated activity in one-fifth of patients with heavily pretreated multiple myeloma.
Benefits of Daratumumab Triplets in Myeloma Sustained With Longer Follow-Up
The benefits of 2 FDA-approved daratumumab–based triplet regimens were sustained in long-term data from 2 pivotal phase III studies presented at the 2016 ASH Annual Meeting.
Gene Expression Studies Offer Insight Into Myeloma Regimen's Efficacy
An analysis of c-MYC expression in relapsed myeloma identified subgroups of patients with improved response to the combination of an immunomodulator and a proteasome inhibitor.
Publication Bottom Border
Border Publication